Key Points
- USANA Health Sciences CFO G. Doug Iiekking sold 5,360 shares on May 27 at an average price of $18.75, totaling about $100,500, according to an SEC filing.
- The company recently beat quarterly expectations, reporting EPS of $0.61 versus the $0.44 consensus and revenue of $250.22 million versus estimates of $240.99 million.
- Despite the earnings beat, analyst sentiment remains cautious, with the stock carrying a consensus rating of “Reduce” and shares trading near $18.90, well below the 52-week high of $38.32.
USANA Health Sciences, Inc. (NYSE:USNA - Get Free Report) CFO G Doug Iiekking sold 5,360 shares of USANA Health Sciences stock in a transaction that occurred on Wednesday, May 27th. The shares were sold at an average price of $18.75, for a total transaction of $100,500.00. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.
USANA Health Sciences Price Performance
Shares of USANA Health Sciences stock opened at $18.90 on Friday. USANA Health Sciences, Inc. has a 1 year low of $16.60 and a 1 year high of $38.32. The firm has a market cap of $348.93 million, a PE ratio of 40.22, a PEG ratio of 0.74 and a beta of 0.77. The company has a 50 day simple moving average of $18.29 and a two-hundred day simple moving average of $19.47.
USANA Health Sciences (NYSE:USNA - Get Free Report) last announced its earnings results on Tuesday, May 5th. The company reported $0.61 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.44 by $0.17. USANA Health Sciences had a net margin of 0.96% and a return on equity of 6.21%. The business had revenue of $250.22 million during the quarter, compared to analyst estimates of $240.99 million. USANA Health Sciences has set its FY 2026 guidance at 1.950-2.290 EPS. As a group, research analysts anticipate that USANA Health Sciences, Inc. will post 2.12 earnings per share for the current year.
Wall Street Analyst Weigh In
Several brokerages have issued reports on USNA. Wall Street Zen lowered shares of USANA Health Sciences from a "buy" rating to a "hold" rating in a research report on Saturday, May 2nd. Weiss Ratings reiterated a "sell (d)" rating on shares of USANA Health Sciences in a research report on Friday, March 27th. Finally, Zacks Research lowered shares of USANA Health Sciences from a "strong-buy" rating to a "hold" rating in a report on Wednesday, April 22nd. One investment analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Reduce".
View Our Latest Stock Analysis on USNA
Institutional Investors Weigh In On USANA Health Sciences
A number of hedge funds have recently made changes to their positions in the business. Pzena Investment Management LLC lifted its holdings in shares of USANA Health Sciences by 1.2% in the 3rd quarter. Pzena Investment Management LLC now owns 1,212,588 shares of the company's stock worth $33,407,000 after acquiring an additional 14,328 shares during the last quarter. Renaissance Technologies LLC lifted its holdings in shares of USANA Health Sciences by 1.9% in the 4th quarter. Renaissance Technologies LLC now owns 1,147,323 shares of the company's stock worth $22,522,000 after acquiring an additional 21,793 shares during the last quarter. Vanguard Group Inc. lifted its holdings in shares of USANA Health Sciences by 5.7% in the 3rd quarter. Vanguard Group Inc. now owns 1,069,032 shares of the company's stock worth $29,452,000 after acquiring an additional 57,249 shares during the last quarter. Dimensional Fund Advisors LP lifted its holdings in shares of USANA Health Sciences by 1.9% in the 3rd quarter. Dimensional Fund Advisors LP now owns 915,049 shares of the company's stock worth $25,210,000 after acquiring an additional 17,318 shares during the last quarter. Finally, Nantahala Capital Management LLC bought a new stake in shares of USANA Health Sciences in the 4th quarter worth approximately $11,485,000. 54.25% of the stock is currently owned by institutional investors.
USANA Health Sciences Company Profile
(
Get Free Report)
USANA Health Sciences, Inc is a Utah‐based company that develops, manufactures and distributes nutritional supplements and personal care products through a network of independent distributors. Founded in 1992 by Dr. Myron Wentz, the company's portfolio includes vitamins, minerals, dietary supplements, weight‐management products and skin‐care formulations. USANA's products are formulated in its own laboratories to meet pharmaceutical‐grade standards, and the company has invested heavily in research and development and quality control to support its offerings.
Operating primarily through a direct selling model, USANA serves markets in North America, Asia Pacific, Europe and Latin America.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
